Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 31 to 40 of 542 total matches.
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
trials included applicationsite
pain (10.6%), dryness (4.9%), exfoliation (4.1%),
erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream
containing the retinoid tretinoin and the oxidizing
agent benzoyl peroxide, for once-daily topical
treatment of acne in patients ≥9 years old.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
a cephalosporin or a carbapenem with
a beta-lactamase inhibitor such as ceftazidime/
avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.
Minocycline Foam (Zilxi) for Rosacea
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
Minocycline Foam (Zilxi) for Rosacea
The FDA has approved a 1.5% topical foam formulation ...
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi – Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved for
this indication. The same manufacturer markets
minocycline foam 4% (Amzeeq) for treatment of acne
in patients ≥9 years old.
Semaglutide (Ozempic) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic –
Novo ...
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of
type 2 diabetes and to reduce the risk of major adverse
cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease, has reduced
body weight significantly in patients with and without
type 2 diabetes when given in addition to lifestyle
intervention. Liraglutide (Saxenda), another GLP-1
receptor agonist, has been FDA-approved for chronic
weight...
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
(CKD).1,2
FINERENONE — Finerenone was approved by
the FDA in 2021 to reduce the risk of sustained ...
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral nonsteroidal
mineralocorticoid receptor antagonist (MRA)
finerenone (Kerendia) to standard treatment in
patients with type 2 diabetes and chronic kidney
disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6 doi:10.58347/tml.2023.1668e | Show Introduction Hide Introduction
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021 (Issue 1622)
and whether
they are are intermittent or persistent (see Table 1).1
H1-ANTIHISTAMINES — Oral second ...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
An EUA for Bamlanivimab and Etesevimab for COVID-19
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
(see Table 1).1
Bamlanivimab received an EUA for use as monotherapy
in such patients in November ...
The FDA has issued an Emergency Use Authorization
(EUA) for Lilly's investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12 years old
who weigh ≥40 kg and are at high risk of progressing
to severe disease and/or hospitalization (see Table 1).
Bamlanivimab received an EUA for use as monotherapy
in such patients in November 2020. Regeneron's
investigational monoclonal antibodies casirivimab
(REGN10933) and imdevimab (REGN10987) are also
authorized for use...
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
–
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing ...
The FDA has approved siponimod (Mayzent –
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod is the second
S1P receptor modulator to be approved in the US;
fingolimod (Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients ≥10
years old, was the first. The purine antimetabolite
cladribine (Mavenclad) was also...
In Brief: New Meningococcal Serogroup B Vaccination Recommendations
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
on Immunization Practices
(ACIP) has issued new recommendations for meningococcal
vaccination.1 Booster ...
The Advisory Committee on Immunization Practices
(ACIP) has issued new recommendations for meningococcal
vaccination. Booster vaccination against
Neisseria meningitidis serogroup B (MenB) is
now recommended in persons at increased risk
for meningococcal disease (see Table 1). MenB
booster doses were not recommended previously for
any population.